Yahoo Finance

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of ...
Yahoo Finance

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of ...
Nasdaq

CERo Therapeutics Announces Promising Preclinical Results for CER-1236 in Ovarian Cancer at 2025 SITC Spring Scientific Presentation

Presentation of encouraging preclinical results for CER-1236 in ovarian cancer, indicating potential effectiveness of the treatment. No observed toxicity in animal models after treatment, highlighting ...
Nasdaq

CERo Therapeutics Initiates Phase 1 Clinical Trial for CER-1236 at TriStar Centennial Medical Center to Treat Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. has announced that TriStar Centennial Medical Center in Nashville, Tennessee, will serve as a clinical trial site for its Phase 1 clinical study of CER-1236, a new ...
PharmaTimes

CERo reports encouraging early data from phase 1 trial of CER‑1236

CER‑T therapy shows initial safety signals and prompts protocol expansion CERo has released new findings from its ongoing phase 1 CertainT‑1 study evaluating CER‑1236, a first‑in‑human chimeric ...
ascopubs.org

Comparative Effectiveness Research in Oncology: An Overview

This Special Issue of Journal of Clinical Oncology provides a broad, in-depth look at the methodologic field that has become known as comparative effectiveness research (CER). The focus is on CER and ...